SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2
(Amendment No. )
Enanta Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
29251M106
(CUSIP Number)
December 31, 2013
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
¨ Rule 13d-1(c)
x Rule 13d-1(d)
| (1) | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 29251M106 | 13G | Page 2 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TVM V Life Science Ventures GmbH & Co KG | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| CUSIP No. 29251M106 | 13G | Page 3 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TVM V Life Science Ventures Management GmbH & Co. KG | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| CUSIP No. 29251M106 | 13G | Page 4 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TVM IV GmbH & Co KG | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| CUSIP No. 29251M106 | 13G | Page 5 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TVM IV Management GmbH & Co. KG | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| CUSIP No. 29251M106 | 13G | Page 6 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TVM Medical Ventures GmbH & Co KG | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| CUSIP No. 29251M106 | 13G | Page 7 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
TVM Capital GmbH | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN | |||||
| CUSIP No. 29251M106 | 13G | Page 8 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Alexandra Goll | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
2,532,119 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
2,532,119 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,532,119 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
14.1% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN | |||||
| CUSIP No. 29251M106 | 13G | Page 9 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Hubert Birner | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
1,617,694 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
1,617,694 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,617,694 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN | |||||
| CUSIP No. 29251M106 | 13G | Page 10 of 20 Pages |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Stefan Fischer | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ¨ (b) ¨ | |||||
| 3 | SEC USE ONLY
| |||||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Germany | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 | SOLE VOTING POWER
0 shares | ||||
| 6 | SHARED VOTING POWER
1,617,694 shares | |||||
| 7 | SOLE DISPOSITIVE POWER
0 shares | |||||
| 8 | SHARED DISPOSITIVE POWER
1,617,694 shares | |||||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,617,694 shares | |||||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
¨ | |||||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9% | |||||
| 12 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN | |||||
| CUSIP No. 29251M106 | 13G | Page 11 of 20 Pages |
Schedule 13G
| Item 1(a). | Name of Issuer: |
Enanta Pharmaceuticals, Inc.
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
The Issuer’s principal executive offices are located at 500 Arsenal Street, Watertown, MA 02472.
| Item 2(a). | Name of Persons Filing: |
This joint statement on Schedule 13G is filed by TVM IV GmbH & Co KG (“TVM IV”), TVM IV Management GmbH & Co. KG, the managing limited partner of TVM IV (“TVM IV Management”), TVM V Life Science Ventures GmbH & Co KG (“TVM V LS”), TVM V Life Science Ventures Management GmbH & Co. KG, the managing limited partner of TVM V LS (“TVM V LS Management”), TVM Medical Ventures GmbH & Co KG (“TVM Medical”), TVM Capital GmbH, the general partner of TVM Medical (“TVM Capital”), Hubert Birner (“Birner”), who is a member of the investment committee of TVM V LS Management, Stefan Fischer (“Fischer”), who is a member of the investment committee of TVM V LS Management, and Alexandra Goll (“Goll”), who is a member of the investment committees of TVM IV Management, TVM V LS Management and TVM Capital and who together with TVM IV, TVM IV Management, TVM V LS, TVM V LS Management, TVM Medical, TVM Capital, Birner and Fischer, are collectively referred to herein as the “Reporting Persons”.
| Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of the Reporting Persons is c/o TVM Capital Group, Ottostr.4, 80333 Munich
| Item 2(c). | Citizenship: |
TVM Capital is a German limited liability company. TVM IV, TVM IV Management, TVM V LS, TVM V LS Management and TVM Medical are German limited partnerships. Birner, Fischer and Goll are citizens of Germany.
| Item 2(d). | Title of Class of Securities: |
Common Stock
| Item 2(e). | CUSIP Number: |
29251M106
| Item 3. | If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
Not applicable.
| CUSIP No. 29251M106 | 13G | Page 12 of 20 Pages |
| Item 4. | Ownership. |
| (a) | Amount beneficially owned: |
TMV IV is the record owner of 523,044 shares of Common Stock (the “TMV IV Shares”). TMV Medical is the record owner of 391,381 shares of Common Stock (the “TMV Medical Shares”). TMV V LS is the record owner of 1,617,694 shares of Common Stock (the “TMV V LS Shares”, together with the TMV IV Shares and the TMV Medical Shares, the “Record Shares”). By virtue of their business affiliations, each Reporting Person, other than Birner and Fischer, may be deemed to beneficially own all of the Record Shares, a total of 2,532,119 shares of Common Stock. Birner and Fischer, as members of the investment committee of TVM V LS Management, may be deemed to own the TMV V LS Shares.
| (b) | Percent of class: |
This percentage is calculated based upon 17,961,713 shares of the Issuer’s Common Stock outstanding as of December 16, 2013, as set forth in Issuer’s Annual Report on Form 10-K for the fiscal year ended September 30, 2013, filed with the Securities and Exchange Commission on December 18, 2013.
| (c) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote: see line 5 of cover sheets. |
| (ii) | Shared power to vote or to direct the vote: see line 6 of cover sheets. |
| (iii) | Sole power to dispose or to direct the disposition of: see line 7 of cover sheets. |
| (iv) | Shared power to dispose or to direct the disposition of: see line 8 of cover sheets. |
Each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.
| Item 5. | Ownership of Five Percent or Less of a Class. |
Not applicable.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. |
Not applicable.
| CUSIP No. 29251M106 | 13G | Page 13 of 20 Pages |
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
| Item 10. | Certification. |
Not applicable. This Schedule 13G is not filed pursuant to Rule 13d-1(b) or Rule 13d-1(c).
| CUSIP No. 29251M106 | 13G | Page 14 of 20 Pages |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2014
| TVM IV GMBH & CO KG | ||||||
| By: | TVM IV MANAGEMENT GMBH & CO. KG, | |||||
| Managing Limited Partner | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM IV MANAGEMENT GMBH & CO. KG | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | ||||||
| By: | TVM V LIFE SCIENCE VENTURES MANAGEMENT GMBH & CO. KG, | |||||
| Managing Limited Partner | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM V LIFE SCIENCE VENTURES MANAGEMENT GMBH & CO. KG | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM MEDICAL VENTURES GMBH & CO KG | ||||||
| By: | TVM CAPITAL GMBH, | |||||
| General Partner | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| CUSIP No. 29251M106 | 13G | Page 15 of 20 Pages |
| TVM CAPITAL GMBH | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| * | ||||||
| Hubert Birner | ||||||
| * | ||||||
| Stefan Fischer | ||||||
| * | ||||||
| Alexandra Goll | ||||||
| /s/ Rolf Starck | ||
| Rolf Starck | ||
| As attorney-in-fact | ||
| * | This Schedule 13G was executed by Rolf Starck on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2. |
| CUSIP No. 29251M106 | 13G | Page 16 of 20 Pages |
EXHIBIT 1
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Enanta Pharmaceuticals, Inc.
Date: February 14, 2014
| TVM IV GMBH & CO KG | ||||||
| By: | TVM IV MANAGEMENT GMBH & CO. KG, | |||||
| Managing Limited Partner | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM IV MANAGEMENT GMBH & CO. KG | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | ||||||
| By: | TVM V LIFE SCIENCE VENTURES MANAGEMENT GMBH & CO. KG, | |||||
| Managing Limited Partner | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM V LIFE SCIENCE VENTURES MANAGEMENT GMBH & CO. KG | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| CUSIP No. 29251M106 | 13G | Page 17 of 20 Pages |
| TVM MEDICAL VENTURES GMBH & CO KG | ||||||
| By: | TVM CAPITAL GMBH, | |||||
| General Partner | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| TVM CAPITAL GMBH | ||||||
| By: | /s/ Josef Moosholzer | |||||
| Josef Moosholzer | ||||||
| Managing Limited Partner | ||||||
| * | ||||||
| Alexandra Goll | ||||||
| * | ||||||
| Hubert Birner | ||||||
| * | ||||||
| Stefan Fischer | ||||||
| /s/ Rolf Starck | ||
| Rolf Starck | ||
| As attorney-in-fact | ||
| * | This Schedule 13G was executed by Rolf Starck on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2. |
| CUSIP No. 29251M106 | 13G | Page 18 of 20 Pages |
EXHIBIT 2
POWER OF ATTORNEY
KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Rolf Starck as the undersigned’s true and lawful attorney-in-fact and agent for him and in his name, place and stead, in any and all capacities, to sign any and all documents relating to any and all Securities and Exchange Commission filings which may be required, granting unto such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that such attorney-in-fact may lawfully do or cause to be done by virtue hereof.
This power shall continue in effect until terminated in writing.
| By: | /s/ Dr. Hubert Birner | |
| Dr. Hubert Birner |
Dated: March 19, 2013
| CUSIP No. 29251M106 | 13G | Page 19 of 20 Pages |
POWER OF ATTORNEY
KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Rolf Starck as the undersigned’s true and lawful attorney-in-fact and agent for him and in his name, place and stead, in any and all capacities, to sign any and all documents relating to any and all Securities and Exchange Commission filings which may be required, granting unto such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that such attorney-in-fact may lawfully do or cause to be done by virtue hereof.
This power shall continue in effect until terminated in writing.
| By: | /s/ Stefan Fischer | |
| Stefan Fischer |
Dated: March 19, 2013
| CUSIP No. 29251M106 | 13G | Page 20 of 20 Pages |
POWER OF ATTORNEY
KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Rolf Starck as the undersigned’s true and lawful attorney-in-fact and agent for him and in his name, place and stead, in any and all capacities, to sign any and all documents relating to any and all Securities and Exchange Commission filings which may be required, granting unto such attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that such attorney-in-fact may lawfully do or cause to be done by virtue hereof.
This power shall continue in effect until terminated in writing.
| By: | /s/ Dr. Alexandra Goll | |
| Dr. Alexandra Goll |
Dated: March 19, 2013